Leerink lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $7 from $9 and keeps a Market Perform rating on the shares. The firm notes Rocket announced via 8-K that the BLA for RP-L102 in Fanconi Anemia has been voluntarily withdrawn. The decision comes on the heels of withdrawing RPL102’s MAA for European approval in July, and the company’s strategic prioritization at Q2 earnings where management announced paused development of RP-L102 and RP-L301 and were pursuing partnerships.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals withdraws BLA for Fanskya
- Rocket Pharmaceuticals Withdraws FDA Application for Gene Therapy
- Rocket Pharmaceuticals Announces Dr. Patel’s Departure Agreement
- Rocket Pharmaceuticals director buys $34.1K in common stock
- Promising Outlook for Rocket Pharmaceuticals: Buy Rating Affirmed Amidst Advancements in RP-A501 Study